A gene edit­ing 3.0 play­er goes deep on cash, fron­tier sci­ence to put pre­ci­sion epi­ge­net­ics to the big test

Is­si Rozen is as deeply em­bed­ded in­to the gene edit­ing field as any­one in the buzzy Cam­bridge, MA biotech hub. As chief busi­ness of­fi­cer and strat­e­gy chief for the Broad over a decade-long stretch, he’d worked with all the big names in a sci­en­tif­ic dis­ci­pline that promis­es to up­end the ther­a­peu­tics field — even­tu­al­ly. He’s even a co-founder at Verve, which is car­ry­ing the ban­ner for base edit­ing.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE